ByHeart Announces New Data Indicating that its First-of-its-Kind, U.S.-Made Infant Formula Improves Sleep Benefits in Infants, According to Clinical Trial Results
NEW YORK, May 3, 2023 /PRNewswire/ -- Today, ByHeart, a next-generation baby nutrition company, announced new data from its clinical trial demonstrating that its infant formula improves sleep benefits in infants. The data collected in the clinical trial established that four-month-old infants who consumed ByHeart's infant formula, at this important time during sleep development, woke up less to feed overnight and slept longer between feeds, compared to infants who consumed another infant formula. These findings build on previously announced ease of digestion and tolerability data published in the Journal of Pediatric Gastroenterology and Nutrition. ByHeart's patented protein blend includes lactoferrin and alpha-lactalbumin, the two most abundant proteins in breast milk; the company is the first to include alpha-lactalbumin at breast milk levels in infant formula in the American market. Babies fed ByHeart had significantly fewer spit-ups and softer stools than babies fed another infant formula, and more closely resembled breastfed infants.